Tiziana Life Sciences to Host Investor Update Call on 2 December 2020 at 4:15 p.m. ET
Tiziana Life Sciences plc (NASDAQ: TLSA), a biotechnology company specializing in therapeutics for oncology and infectious diseases, announced a conference call led by CEO and CSO Dr. Kunwar Shailubhai on December 2, 2020, at 4:15 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Tiziana Life Sciences plc (NASDAQ: TLSA), a biotechnology company specializing in therapeutics for oncology and infectious diseases, announced a conference call led by CEO and CSO Dr. Kunwar Shailubhai on December 2, 2020, at 4:15 p.m. ET. The call will cover the company's transition from AIM to the London Stock Exchange's Standard Segment, updates on ongoing clinical trials, and recent developments. Individuals unable to attend can access a replay until December 16, 2020. The company is known for its innovative treatments, including Milciclib and Foralumab, addressing various autoimmune diseases.
Details
News Market Reaction – TLSA
The recorded move for TLSA in the trading session of this news was +4.02%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and LONDON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced its CEO and CSO Dr. Kunwar Shailubhai will host a conference call on Wednesday, 2 December 2020 at 4:15 p.m. ET to provide updates on the Company. Dr. Shailubhai will provide updates on the Company’s proposed move from AIM to the Standard Segment of the Main Market of the London Stock Exchange, ongoing clinical trials, as well as other recent developments in Tiziana Life Sciences.
| Date: | Wednesday, 2 December 2020 |
| Time: | 4:15 p.m. Eastern Time |
| Live Call: | +1-877-425-9470 (U.S. Toll-Free) or +1-201-389-0878 (International) |
| Webcast: | http://public.viavid.com/index.php?id=142634 |
For interested individuals unable to join the conference call, a dial-in replay of the call will be available until 16 December 2020 and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 13713850.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.
For further enquiries:
United Kingdom Investors:
| Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder | +44 (0)20 7495 2379 |
United States Investors:
| Dave Gentry RedChip Companies Inc. | Office 1 800 RED CHIP (733 2447) Cell 407-491-4498 (USA) dave@redchip.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.